Short Interest in Tema Heart & Health ETF (NASDAQ:HRTS) Drops By 50.8%

Tema Heart & Health ETF (NASDAQ:HRTS) was the recipient of a large drop in short interest in August. As of August 14th, there was short interest totaling 2,508 shares, a drop of 50.8% from the July 30th total of 5,095 shares. Based on an average daily volume of 3,207 shares, the short-interest ratio is currently 0.8 days. Approximately 0.2% of the shares of the stock are short sold.

Tema Heart & Health ETF Stock Performance

Tema Heart & Health ETF stock traded down $0.30 on Monday, reaching $37.34. The company’s stock had a trading volume of 3,462 shares, compared to its average volume of 5,968. The company has a market cap of $55.64 million, a price-to-earnings ratio of 22.06 and a beta of 0.63. The business’s fifty day moving average price is $36.89 and its 200 day moving average price is $35.15. Tema Heart & Health ETF has a twelve month low of $29.45 and a twelve month high of $38.87.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC acquired a new stake in Tema Heart & Health ETF in the 4th quarter valued at about $27,000. JPMorgan Chase & Co. acquired a new position in shares of Tema Heart & Health ETF during the second quarter worth approximately $63,000. XML Financial LLC acquired a new position in shares of Tema Heart & Health ETF during the second quarter worth approximately $223,000. Citadel Advisors LLC bought a new stake in shares of Tema Heart & Health ETF during the third quarter valued at approximately $243,000. Finally, Anson Capital Inc. bought a new stake in shares of Tema Heart & Health ETF during the second quarter valued at approximately $297,000.

Tema Heart & Health ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.